Grincamycin B Functions as a Potent Inhibitor for Glioblastoma Stem Cell via Targeting RHOA and PI3K/AKT.
Grincamycin B
PI3K/AKT
RHOA
glioblastoma
glioma stem cells
Journal
ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337
Informations de publication
Date de publication:
05 08 2020
05 08 2020
Historique:
pubmed:
26
6
2020
medline:
22
6
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is the most malignant form of glioma, and the overall survival time of patients with GBM is usually less than 14 months. Therefore, it is urgent to find new and effective medicine for GBM. Recently, marine natural products have been shown to exhibit strong inhibitory effects on cancer cells, providing a new avenue for exploring novel drugs for GBM treatment. In this study, we investigated the inhibitory effect of the Grincamycin (GCN) B-F, newly isolated from marine-derived Streptomyces Lusitanus SCSIO LR32, on GBM cells, and evaluated the mechanism of GCN B on GBM. The results, for the first time, showed that GCN B acted as a potent inhibitor to suppress growth and invasion of two human GBM cell lines U251 and 091214
Identifiants
pubmed: 32584547
doi: 10.1021/acschemneuro.0c00206
doi:
Substances chimiques
Anthraquinones
0
grincamycin
113395-84-9
RHOA protein, human
124671-05-2
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
rhoA GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM